Adrenocortical oncocytoma
11 Case reports and review of the literature

Yazhao Hong, MD, Yuanyuan Hao, MD, Jinghai Hu, MD, Bo Xu, MD, Hongli Shan, MD, PhD,*, Xiaoqing Wang, MD, PhD,†*

Abstract
Rationale: Adrenocortical oncocytoma is an extremely rare tumor of the adrenal gland. Its diagnostic criteria and biological behavior has not yet reached a consensus. The purpose of this study is to investigate the clinical characteristics of adrenocortical oncocytoma.

Patient concerns: The clinical data from 11 cases of adrenocortical oncocytoma were retrospectively analyzed. Five patients found the tumor incidentally during the healthy examination, and 3 cases found the tumor during the diagnostic work-up for the evaluation of flank pain or hypertension. A female patient manifested virilization, and Cushing’s syndrome showed in two patients. The tumor diameter was ranging from 2.0-13.0 cm.

Diagnoses: The serum cortisol, plasma aldosterone and catecholamine metabolites were used to evaluate the function of the tumors, and enhanced CT scan was used to confirm the tumor boundary, enhancement, and lymph nodes condition.

Interventions: Seven cases underwent laparoscopic adrenal tumor resection, 4 patients underwent open surgery. Pathological report indicated adrenocortical oncocytoma in all cases, three of which were potentially malignant.

Outcomes: The patients were followed up for 19-72 months, no local recurrence and distant metastases were detected in 3 cases of malignant potential cases.

Lessons: The majority of adrenocortical oncocytoma with or without function are benign, and close follow-up observation is essential.

Abbreviations: CT = computed tomography, CgA = chromogranin A, CK = cytokeratin, F = female, HPF = high power field, L = left, M = male, MRI = magnetic resonance imaging, R = right, VMA = vanillylmandelic acid.

Keywords: adrenal tumor, adrenocortical oncocytoma, malignant potential, treatment

1. Introduction

Oncocytes can occur in various organs, notably the kidney, thyroid, pituitary, salivary, parathyroid and lacrimal glands as well as the skin, respiratory, and gastrointestinal tracts. It is composed of oncocytes, which are epithelial cells with acidophilic, granular cytoplasm packed with mitochondria. They are usually benign lesions but have an unpredictable malignant potential.[1]

Adrenocortical oncocytoma is an extremely rare tumor of the adrenal gland. It was first reported by Kakimoto[2] in 1986. Since then, no more than 120 cases of adrenocortical oncocytoma have been reported in the English-language literature. Its diagnostic criteria and biological behavior have not yet reached a consensus.[3,4] Most of oncocytomas are detected occasionally in health check-up, but it is still difficult to identify. Adrenal oncocytoma was described as a nonfunctional or functional benign neoplasm with a malignant potential.[3,4] Here, we report 11 patients with adrenal cortical oncocytoma and also make a summary of the clinical and pathological features, as well as diagnostic and treatment points of adrenocortical oncocytoma. This study may have the largest sample size in a single center.

2. Case presentations

The study protocol was approved by the Ethics Committee of the First Hospital of Jilin University. Clinical records of 11 patients with an adrenal oncocytoma, diagnosed and treated at the First Hospital of Jilin University, between January 2008 and January 2012, were retrospectively analyzed. The demographic and clinical data for the patients are listed in Table 1. The group contains 5 males and 6 females; the age range was 6 to 58 years. Five patients found the tumor incidentally during the healthy examination, and 3 cases found the tumor during the diagnostic work-up for the evaluation of flank pain or hypertension. A female patient manifested virilization, such as too much body hair, rough skin, and irregular menstruation; Cushing’s syndrome showed in 2 patients. The serum cortisol, plasma aldosterone, and catecholamine metabolites were normal except for Cushing’s syndrome cases. The CT scan showed that the tumor diameter ranges from 2.0 to 13.0 cm and the CT value is 35 to 48 HU. Enhanced CT showed that 4 lesions can be homogeneously enhanced, whereas the remaining 7 cases are heterogeneous enhancement (Fig. 1). The boundaries between tumor and...
surrounding tissue were all clear. Seven patients were preoperatively prepared as pheochromocytoma due to the large tumor size, and phenoxybenzamine and blood volume expansion were given. Seven cases underwent laparoscopic adrenal tumor resection, and 4 patients underwent open surgery of adrenal tumors, with tumor diameter ranging from 6.0 to 13 cm. All procedures were successfully performed and no Clavien >2 complications occurred. The tumor specimens were yellow or yellow-brown, encapsulated, and necrosis is common in bulky tumors. Pathological report indicates adrenal cortical oncocytoma in all cases, 3 of which were potentially malignant (Fig. 2). The patients were followed up for 19 to 72 months. The masculine hairy symptoms of the female case disappeared. The symptoms of moon face, buffalo hump also disappeared in 2 cases of the Cushing syndrome cases, at the same time serum cortisol decreased to the normal level. No local recurrence and distant metastases were detected in 3 cases of malignant potential cases.

3. Discussion

Overall incidence of oncocytoma is relatively common in kidney, thyroid, and salivary glands. It can also be found in pituitary, eyelids, parathyroid, thymus, spinal cord, and other parts. So, the adrenal cortical oncocytoma is a rare disease with an unknown incidence. No identified environmental or genetic risk factor was reported for the etiology of the tumor. It is commonly found in patients between 15 and 77 years. F/M is 2.5/1, and L/R is 3.5/1. In the literature, the majority of oncocytoma in the adrenal cortex are nonfunctioning. According to the latest report, 31.5% of the adrenal oncocytoma are related to hormone abnormalities, including hypercortisolism and sex hormone abnormalities. The most common clinical manifestations are Cushing’s syndrome, masculine and feminine. Another system

Table 1

| No. | Age, years | Sex | Site | Tumor size, cm | Symptoms/Findings at diagnosis | Cortisol | Aldosterone | Testosterone | VMA | Histological diagnosis | Inhibin | CK | Vimentin | CgA | Follow-up |
|-----|------------|-----|------|---------------|--------------------------------|----------|-------------|--------------|-----|-----------------------|--------|-----|----------|-----|-----------|
| 1   | 24         | F   | R    | 10            | Flank pain                     | N        | N           | N            | N   | Oncocytoma, malignant potential | +      | -   | -        | -   | 19        |
| 2   | 5          | M   | R    | 3.5           | Healthy examination            | N        | N           | N            | N   | Oncocytoma               | +      | -   | +        | -   | 24        |
| 3   | 49         | F   | R    | 2.0           | Hypertension, Cushing syndrome  | H        | N           | N            | N   | Oncocytoma               | +      | -   | -        | -   | 38        |
| 4   | 30         | M   | R    | 6.0           | Healthy examination            | N        | N           | N            | N   | Oncocytoma               | +      | +   | -        | -   | 42        |
| 5   | 46         | M   | R    | 12.0          | Healthy examination            | N        | N           | N            | N   | Oncocytoma, malignant potential | +      | -   | -        | -   | 45        |
| 6   | 36         | F   | L    | 3.0           | Manifested virilization        | N        | N           | H            | N   | Oncocytoma               | +      | -   | +        | -   | 48        |
| 7   | 23         | F   | R    | 3.5           | Hypertension, Cushing syndrome  | H        | N           | N            | N   | Oncocytoma               | +      | -   | -        | -   | 54        |
| 8   | 46         | F   | L    | 4.0           | Healthy examination            | N        | N           | N            | N   | Oncocytoma               | +      | +   | -        | -   | 60        |
| 9   | 34         | F   | R    | 7.0           | Healthy examination            | N        | N           | N            | N   | Oncocytoma               | +      | -   | -        | -   | 63        |
| 10  | 56         | M   | R    | 9.0           | Hypertension                   | N        | N           | N            | N   | Oncocytoma               | +      | +   | -        | -   | 36        |
| 11  | 27         | M   | L    | 3.0           | Hypertension                   | N        | N           | N            | N   | Oncocytoma, adrenal hyperplasia | +      | -   | -        | -   | 72        |

CgA = chromogranin A, CK = cytokeratin, VMA = vanillylmandelic acid.
review showed that only 17% are functional adrenal masses, and an adrenocortical oncocytic neoplasm occurring with a Cushing’s syndrome, pheochromocytoma, or aldosteronoma had been described. In this study, the youngest patient is only 5 years old, and 2.3% (3/111) patients had the functional tumors. According to the clinical complain and laboratory examination, 2 cases were diagnosed as Cushing’s syndrome, and 1 case was women masculine. Our results may conclude that adrenocortical oncocytoma may be a functional tumor.

The adrenocortical oncocytoma has no imaging characteristic performance, so it is difficult to confirm the diagnosis preoperatively. The tumor is usually large in size, but has a complete capsule, showing a non invasive growth pattern. In the CT scan, the density is relatively uniform, and the CT value is 20 to 40 HU. In enhanced CT, it shows inhomogeneous enhancement. In this study, the tumor diameter ranged from 2 to 13 cm. The CT value was 35 to 48 HU. Enhanced CT showed 4 cases of moderate homogeneous enhancement, and the remaining 7 cases were heterogeneous enhancement.

The management of adrenal mass is surgical removal and the approach depends upon the size and function. Open surgery was the traditional approach for the management of adrenal tumors. With the development of endoscopic techniques, laparoscopic adrenalectomy has become the gold standard for the small adrenal tumors. Compared with open surgery, the laparoscopic surgery has the benefit of less bleeding, faster recovery, and shorter hospital stay. However, for the tumors larger than 6 cm and/or of potentially malignancy, because of its high transfer rate and the incidence of complications, laparoscopic adrenalectomy remains controversial. In this study, 7 cases underwent laparoscopic adrenal adenoma resection, in which the largest tumor diameter was 8 cm. No serious complications occurred. We think that laparoscopic resection of adrenal tumors is safe. Especially in following circumstances that preoperative CT and MRI results indicate the tumor is encapsulated, the boundaries between tumor and surrounding tissue is clear, no regional lymph nodes invasion.

The diagnosis of adrenocortical oncocytoma is mainly based on histological and immunohistochemistry. Typical oncocytoma is dark brown, and the tumor cells have the same size, with low-fat droplets granular, eosinophilic cytoplasm, with the nuclear in on histological and immunohistochemistry. Typical oncocytoma tissue is clear, no regional lymph nodes invasion.

The management of adrenal mass is surgical removal and the approach depends upon the size and function. Open surgery was the traditional approach for the management of adrenal tumors. With the development of endoscopic techniques, laparoscopic adrenalectomy has become the gold standard for the small adrenal tumors. Compared with open surgery, the laparoscopic surgery has the benefit of less bleeding, faster recovery, and shorter hospital stay. However, for the tumors larger than 6 cm and/or of potentially malignancy, because of its high transfer rate and the incidence of complications, laparoscopic adrenalectomy remains controversial. In this study, 7 cases underwent laparoscopic adrenal adenoma resection, in which the largest tumor diameter was 8 cm. No serious complications occurred. We think that laparoscopic resection of adrenal tumors is safe. Especially in following circumstances that preoperative CT and MRI results indicate the tumor is encapsulated, the boundaries between tumor and surrounding tissue is clear, no regional lymph nodes invasion.

The diagnosis of adrenocortical oncocytoma is mainly based on histological and immunohistochemistry. Typical oncocytoma is dark brown, and the tumor cells have the same size, with low-fat droplets granular, eosinophilic cytoplasm, with the nuclear in center, arranged in the beam-like hollow tubular structures, occasionally forming microcystis cavity surrounded by slender fibrous septa. A small amount of lymphocytic infiltration can be discovered in the interstitial. Under the electron microscope, in cytoplasm, there are quantities of mitochondria with layered and bubbly ridge, and small electron-dense inclusion bodies. Few oncocytoma has mitotic and necrotic. In this study, all cases were pathologically diagnosed as adrenal cortical oncocytoma. Immunohistochemical results showed 3 cases of malignant potential. However, a strong, hormonally active tumor (especially in Cushing’s syndrome or in hyperandrogenism) can also have compact eosinophilic cells without lipid vacuoles, and whether such tumors belong to oncocytoma remains controversial.

Further work should be done to define the adrenal oncocytoma in accuracy.

Most of the adrenocortical oncocytomas are benign; only a few tumors were diagnosed as malignant. It is reported that about 22% of patients showed malignant potential. Tumor size and weight are important biological behavior indicators, but these are not accurate indicators. They should be combined with clinical manifestations, biochemical test results, and histological features. Moreover, the Weiss system is a guideline to distinguish benign and malignant neoplasm, but the Weiss system adrenal is not completely reliable. Therefore, Bisciglia et al modified the Weiss system according to the pathological features of adrenal cortex eosinophilus tumor as follows: mitosis count > 5/50 HPF, atypical mitosis and venous invasion as the main criteria, and tumor diameter > 10 cm and (or) weight > 200 g, necrosis, capsular invasion, and sinusoids infiltration as the secondary criteria. If it meets any one of the main criteria can be diagnosed as histologically malignant. If it meets one or more secondary criteria, it can be considered as malignant potential. The ones that do not meet any of the main and secondary criteria are benign. In this study, 8 cases were benign because they met neither major criteria nor minor criteria. Although 3 cases were diagnosed malignant potential in condition that they met the secondary criteria, we did not see any metastasis and recurrence during the follow-up. Argyriou et al reported 1 case with a tumor relapse, and it was the only 1 case in the literature. However, the patient had a history of adrenocortical carcinoma, and the diagnosis criteria used by the author aroused a controversy. Therefore, adrenocortical oncocytoma can be treated as a benign tumor. As a result, if the biopsy of an incidental adrenal tumor showed an oncocytoma, the tumor could be safely observed. However, an officially established histological scoring system is needed, and strict follow-up in the future is indispensable.

4. Conclusions
The adrenocortical oncocytoma is a rare tumor with or without function. Surgical removal is still the major treatment method. This disease can be treated as a benign tumor. However, molecular studies, precise diagnosis criteria, large clinical samples, and longer follow-up are needed to confirm the results.

References
[1] Chang A, Harawi SJ. Oncocytes, oncocytosis, and oncocytic tumors. Pathol Ann 1992;27(pt 1):263–304.
[2] Kakimoto S, Yushita Y, Sanefuji T, et al. Non-hormonal adrenocortical adenoma with oncocytoma-like appearances [J]. Hinyokika Kiyo 1986;32:757–63.
[3] Peppa M, Karamitopoulos E, Nikolopoulos P, et al. Large adrenal oncocytoma with uncertain malignant potential: case report and review of literature. Endocr Pract 2010;16:641–5.
[4] Lee CK, Choi KH, Cha YJ, et al. Large oncocytic adrenocortical tumor with uncertain malignant potential. Korean J Urol 2011;52:630–2.
[5] Argyriou P, Zissis C, Alevizopoulos N, et al. Adrenocortical oncocytoma with recurrent metastases: a case report and review of the literature. World J Surg Oncol 2008;6:134.
[6] Farah-Klibi F, Ben Slama S, Ferchichi L, et al. Adrenal gland oncocytoma. Tunis Med 2011;89:309–10.
[7] Monk IP, Lahiri R, Swapakasam R, et al. Adrenocortical oncocytoma: review of imaging and histopathological implications. Int J Surg Case Rep 2010;1:30–2.
[8] Wong DD, Spagnolo DV, Bisceglia M, et al. Oncocytic adrenocortical neoplasms—a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. Hum Pathol 2011;42:489–99.
[9] Lee SS, Baek KH, Lee YS, et al. Subclinical Cushing’s syndrome associated with an adrenocortical oncocytoma. J Endocrinol Invest 2008;31:675–9.
[10] Meairini L, Del Sordo R, Costantini E, et al. Adrenal oncocytic neoplasm: a systematic review. Urol Int 2013;91:125–33.
[11] Yordanova G, Iotova V, Kalchem K, et al. Virilizing adrenal oncocytoma in a 9-year-old girl: rare neoplasm with an intriguing postoperative course. J Pediatr Endocrinol Metab 2013;26:685–90.
[12] Shah RK, Otto A, Ozkan OS, et al. Adrenal oncocytoma: US and CT findings. JBR-BTR 2004;87:180–2.
[13] Lupascu C, Tarceaveau E, Bradea C, et al. Laparoscopic adrenalectomy for large solid cortical tumours—is it appropriate? Chirurgia (Bucur) 2011;106:315–20.
[14] Machado NO, Al Qadhi H, Al Wahaibi K, et al. Laparoscopic adrenalectomy for large adrenocortical carcinoma. JSLS 2015;19.

[15] Mesci A, Celik O, Akand M, et al. Evaluation of laparoscopic transperitoneal adrenalectomy: is it feasible for large masses? Minerva Urol Nefrol 2015;67:175–8.

[16] Munoz de Nova JL, Garcia-Sanz I, del Campo Val L, et al. Oncocytoma: an uncommon lesion for adrenal gland. Endocrinol Nutr 2015;62:144–5.

[17] Shah VN, Premkumar A, Walia R, et al. Large but benign adrenal mass: adrenal oncocytoma. Indian J Endocrinol Metab 2012;16:469–71.

[18] Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984;8:163–9.

[19] Bisceglia M, Ludovico O, Di Mattia A, et al. Adrenocortical oncocytic tumors: report of 10 cases and review of the literature. Int J Surg Pathol 2004;12:231–43.